Evidence map›Paper›PMID 28270931›Full record

ArticleCanadian journal of kidney health and disease2017

Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.

Kelly R McMahon, Shahrad Rod Rassekh, Kirk R Schultz, Maury Pinsk, Tom Blydt-Hansen, Cherry Mammen, Ross T Tsuyuki, Prasad Devarajan, Geoff D E Cuvelier, Lesley G Mitchell and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of kidney health and disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 2 countries.

Kelly R McMahonDepartment of Pediatrics, Division of Pediatric Nephrology, Montreal Children's Hospital, McGill University Health Centre, Montreal, Canada.
Shahrad Rod RassekhDepartment of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplantation, British Columbia Children's Hospital, University of British Columbia, Vancouver, Canada.
Kirk R SchultzDepartment of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplantation, British Columbia Children's Hospital, University of British Columbia, Vancouver, Canada.
Maury PinskDepartment of Pediatrics and Child Health, CancerCare Manitoba, University of Manitoba, Winnipeg, Canada.
Tom Blydt-HansenDepartment of Pediatrics, Division of Pediatric Nephrology, British Columbia Children's Hospital, University of British Columbia, Vancouver, Canada.
Cherry MammenDepartment of Pediatrics, Division of Pediatric Nephrology, British Columbia Children's Hospital, University of British Columbia, Vancouver, Canada.
Ross T TsuyukiFaculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Prasad DevarajanDivision of Nephrology & Hypertension, Cincinnati Children's Hospital Medical Center, OH, USA.
Geoff D E CuvelierDepartment of Pediatrics and Child Health, CancerCare Manitoba, University of Manitoba, Winnipeg, Canada.
Lesley G MitchellDepartment of Pediatrics, Division of Hematology/Oncology, Stollery Children's Hospital, University of Alberta, Edmonton, Canada.
Sylvain BaruchelDepartment of Pediatrics, Division of Hematology/Oncology, Hospital for Sick Children, Toronto, Canada.
Ana PalijanDepartment of Pediatrics, Division of Pediatric Nephrology, Montreal Children's Hospital, McGill University Health Centre, Montreal, Canada.
Bruce C CarletonChild and Family Research Institute, University of British Columbia, Vancouver, Canada.
Colin J D RossChild and Family Research Institute, University of British Columbia, Vancouver, Canada.
Michael ZappitelliDepartment of Pediatrics, Division of Pediatric Nephrology, Montreal Children's Hospital, McGill University Health Centre, Montreal, Canada.
Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Group
BC Children's Hospital · CAMontreal Children's Hospital · CAUniversity of Alberta · CAUniversity of British Columbia · CACancerCare Manitoba · CAChild and Family Research Institute · CACincinnati Children's Hospital Medical Center · USHospital for Sick Children · CAMcGill University Health Centre · CAUniversity of Manitoba · CA

Funding

Proteomics CoreP50DK096418 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI DEVARAJAN, PRASAD · 2012 to 2021
$8.4M
NIDDK NIH HHS P50 DK096418
6 · The paper itself

Abstract

backgroundChildhood cancer survivors experience adverse drug events leading to lifelong health issues. The Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) team was established to validate and apply biomarkers of cancer treatment effects, with a goal of identifying children at high risk of developing cancer treatment complications associated with thrombosis, graft-versus-host disease, hearing loss, and kidney damage. Cisplatin is a chemotherapy well known to cause acute and chronic nephrotoxicity. Data on biomarkers of acute kidney injury (AKI) and late renal outcomes in children treated with cisplatin are limited.

objectiveTo describe the design and methods of the pan-Canadian ABLE Nephrotoxicity study, which aims to evaluate urine biomarkers (neutrophil gelatinase-associated lipocalin [NGAL] and kidney injury molecule-1 [KIM-1]) for AKI diagnosis, and determine whether they predict risk of long-term renal outcomes (chronic kidney disease [CKD], hypertension).

designThis is a 3-year observational prospective cohort study.

settingThe study includes 12 Canadian pediatric oncology centers. PATIENTS: The target recruitment goal is 150 patients aged less than 18 years receiving cisplatin. MEASUREMENTS: Serum creatinine (SCr), urine NGAL, and KIM-1 are measured during cisplatin infusion episodes (pre-infusion, immediate post-infusion, discharge sampling). At follow-up visits, eGFR, microalbuminuria, and blood pressure are measured and outcomes are collected.

methodsLIMITATIONS: The study has a relatively moderate sample size and short follow-up duration. There is potential for variability in data collection since multiple sites are involved.

conclusionsABLE will provide a national platform to study biomarkers of late cancer treatment complications. The Nephrotoxicity study is a novel study of AKI biomarkers in children treated with cisplatin that will greatly inform on late cisplatin renal outcomes and follow-up needs.

Indexed as

acute kidney injurycisplatin nephrotoxicitycohort studypediatricsurinary biomarkers

Identifiers

PMID28270931
PMCPMC5317038
OpenAlexW2588909661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.